Activate anti-tumor immunity: Promote the expansion and differentiation of progenitor cell-depleted CD8+ T cells; enhance the efficacy of immune checkpoint inhibitors and PARP inhibitors; facilitate the formation of tertiary lymphoid structures. This evidence concerns the gene CD8A and neoplasm.